

## Supplementary Material

This appendix has been provided by the authors to give readers additional information about their work.

### Effect of omega-3 LCPUFA supplementation on maternal fatty acid and oxylipin concentrations during pregnancy

#### Contents

Supplementary Table 1. Oxylipins screened and their parent FFA and PUFA .....	2
Supplementary Table 2: Descriptive statistics for concentration of fatty acids derivatives and oxylipins at baseline by treatment group .....	4
Supplementary Table 3: Effect of treatment group and time on concentration of fatty acids and oxylipins .....	6
Supplementary Table 4: Effect of high vs low baseline total omega-3 status (>4.9% vs ≤4.1%), treatment group and time on concentration of DHA & oxylipins and total omega-3. ....	9
Supplementary Figure 1. Effect of baseline total omega-3 status, treatment group and time on concentration of free DHA. ....	10
Supplementary Figure 2. Effect of baseline total omega-3 status, treatment group and time on concentration of 4-HDHA. ....	11
Supplementary Figure 3. Effect of baseline total omega-3 status, treatment group and time on concentration of 7-HDHA. ....	12
Supplementary Figure 4. Effect of baseline total omega-3 status, treatment group and time on concentration of free total omega-3.....	13

**Supplementary Table 1. Oxylipins screened and their parent FFA and PUFA**

<b>PUFA</b>	<b>FFA</b>	<b>Oxylipin</b>	<b>Oxylipin abbreviation</b>
<b>n-6 PUFA</b>	LA	9,10 epoxy-hydroxy-octadecenoic acid	9,10 EpHOME
		9-oxo-octadecadienoic acid	9-oxoODE
		13-hydroxy-octadecadienoic acid	13-HODE
		12,13 dihydroxy-octadecenoic acid	12,13DiHOME
	AA	5-hydroxy-eicosatetraenoic acid	5-HETE
		8-hydroxy-eicosatetraenoic acid	8-HETE
		9-hydroxy-eicosatetraenoic acid	9-HETE
		11-hydroxy-eicosatetraenoic acid	11-HETE
		12-hydroxy-eicosatetraenoic acid	12-HETE
		15-hydroxy-eicosatetraenoic acid	15-HETE
		20-hydroxy-eicosatetraenoic acid	20-HETE
		5,6-epoxy-eicosatrienoic acid	5,6-EET
		8,9-epoxy-eicosatrienoic acid	8,9-EET
		11,12-epoxy-eicosatrienoic acid	11,12-EET
		14,15-epoxy-eicosatrienoic acid	14,15-EET
		leukotriene B4	LTB4
		lipoxin A4	LXA4
		lipoxin B4	LXB4
		Prostaglandin E2	PGE2
		Prostaglandin F2	PGF2
Prostaglandin D2	PGD2		
Thromboxane B2	TXB2		
<b>n-3 PUFA</b>	EPA	18-hydroxy-eicosapentaenoic acid	18-HEPE
	DHA	4-hydroxy-docosahexaenoic acid	4-HDHA
		7-hydroxy-docosahexaenoic acid	7-HDHA

<b>PUFA</b>	<b>FFA</b>	<b>Oxylipin</b>	<b>Oxylipin abbreviation</b>
		14-hydroxy-docosahexaenoic acid	14-HDHA
		10,17-dihydroxy-docosahexaenoic acid	10,17-DiHDHA
		16,17epoxy docosapentaenoic acid	16,17EpDPA
		19,20epoxy docosapentaenoic acid	19,20EpDPA
		Resolvin D1	RevD1

PUFA, polyunsaturated fatty acids; FFA, free fatty acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid

**Supplementary Table 2: Descriptive statistics for concentration of fatty acids derivatives and oxylipins at baseline by treatment group**

Characteristic		DHA (n=614)	Control (n=649)	Total (n=1263)
<b>DHA</b>				
4-HDHA: Mean (SD)		18.0 (21.5)	17.1 (15.9)	17.6 (18.9)
7-HDHA: Mean (SD)		1.0 (1.4)	1.0 (0.7)	1.0 (1.1)
14-HDHA: Mean (SD)		7.2 (7.4)	7.9 (9.8)	7.6 (8.7)
10,17-DiHDHA*: N(%)				
	Not detected	545 (88.8)	560 (86.3)	1105 (87.5)
	Detected	69 (11.2)	89 (13.7)	158 (12.5)
16,17EpDPA*: N(%)				
	Not detected	407 (66.3)	413 (63.6)	820 (64.9)
	Detected	207 (33.7)	236 (36.4)	443 (35.1)
19,20EpDPA: Mean (SD)		0.3 (0.4)	0.3 (0.3)	0.3 (0.3)
<b>EPA</b>				
18-HEPE: Mean (SD)		2.5 (3.4)	2.4 (2.7)	2.5 (3.1)
<b>AA</b>				
5-HETE: Mean (SD)		129.4 (121.7)	124.8 (81.2)	127.0 (102.8)
8-HETE: Mean (SD)		6.0 (5.5)	6.1 (3.9)	6.0 (4.7)
9-HETE : Mean (SD)		6.5 (5.4)	7.1 (6.1)	6.8 (5.8)
11-HETE: Mean (SD)		28.5 (28.0)	28.7 (19.2)	28.6 (23.9)
12-HETE: Mean (SD)		133.0 (118.2)	142.9 (136.8)	138.1 (128.1)
15-HETE: Mean (SD)		8.6 (6.8)	8.7 (5.1)	8.6 (6.0)
20-HETE*: N(%)				
	Not detected	597 (97.2)	634 (97.7)	1231 (97.5)
	Detected	17 (2.8)	15 (2.3)	32 (2.5)
5,6-EET*: N(%)				
	Not detected	585 (95.3)	616 (94.9)	1201 (95.1)
	Detected	29 (4.7)	33 (5.1)	62 (4.9)
8,9-EET*: N(%)				

<b>Characteristic</b>		<b>DHA (n=614)</b>	<b>Control (n=649)</b>	<b>Total (n=1263)</b>
11,12-EET*: N(%)	Not detected	531 (86.5)	537 (82.7)	1068 (84.6)
	Detected	83 (13.5)	112 (17.3)	195 (15.4)
14,15-EET: Mean (SD)	Not detected	588 (95.8)	629 (96.9)	1217 (96.4)
	Detected	26 (4.2)	20 (3.1)	46 (3.6)
LTB4: Mean (SD)		2.1 (1.6)	2.1 (1.5)	2.1 (1.5)
LXA4: Mean (SD)		3.2 (2.7)	3.1 (2.2)	3.1 (2.4)
LXB4: Mean (SD)		0.3 (0.3)	0.3 (0.3)	0.3 (0.3)
Prostaglandin E2*: N(%)		3.8 (5.9)	3.6 (5.6)	3.7 (5.7)
Prostaglandin F2*: N(%)	Not detected	596 (97.1)	630 (97.1)	1226 (97.1)
	Detected	18 (2.9)	19 (2.9)	37 (2.9)
Prostaglandin D2: Mean (SD)	Not detected	610 (99.3)	642 (98.9)	1252 (99.1)
	Detected	4 (0.7)	7 (1.1)	11 (0.9)
Thromboxane B2: Mean (SD)		10.6 (9.9)	9.7 (8.7)	10.2 (9.3)
		7.7 (8.8)	8.0 (9.2)	7.9 (9.0)
<b>LA</b>				
9,10 EpHOME: Mean (SD)		6.7 (4.8)	6.8 (5.2)	6.8 (5.0)
9-Oxoode: Mean (SD)		53.4 (44.3)	54.6 (36.6)	54.0 (40.5)
13-HODE: Mean (SD)		97.9 (81.5)	100.3 (71.3)	99.1 (76.4)
12,13DiHOME: Mean (SD)		1.2 (1.3)	1.1 (1.2)	1.1 (1.3)

LA, linoleic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid

\* No statistical analysis performed on oxylipin due to the majority of values falling below the limit of detection.

Supplementary Table 3: Effect of treatment group and time on concentration of fatty acids and oxylipins

Fatty Acid or Oxylipin	Omega-3 Baseline Mean (SD)	Control Baseline Mean (SD)	Omega-3 34 weeks Mean (SD)	Control 34 weeks Mean (SD)	Omega-3 Group Effect*	Control Group Effect*	Difference**
<b>OMEGA-3 FATTY ACIDS</b>							
<b>DHA and DHA derived metabolites</b>							
Total DHA	2.7 (0.6)	2.8 (0.7)	3.3 (0.9)	2.4 (0.5)	0.60 (0.52, 0.68)	-0.33 (-0.37, -0.28)	0.93 (0.83, 1.02)
Free DHA	0.9 (0.5)	0.9 (0.4)	0.7 (0.4)	0.5 (0.2)	-0.16 (-0.21, -0.11)	-0.38 (-0.41, -0.34)	0.21 (0.15, 0.27)
4-HDHA	18.0 (21.5)	17.1 (15.9)	13.6 (12.6)	9.7 (7.3)	-4.37 (-6.36, -2.38)	-7.37 (-8.73, -6.01)	2.99 (0.57, 5.41)
7-HDHA	1.0 (1.4)	1.0 (0.7)	1.2 (1.0)	0.8 (0.4)	0.13 (0.00, 0.26)	-0.21 (-0.27, -0.15)	0.34 (0.20, 0.49)
14-HDHA	7.2 (7.4)	7.9 (9.8)	6.3 (8.8)	4.0 (3.6)	-0.90 (-1.79, -0.01)	-3.95 (-4.75, -3.15)	3.05 (1.85, 4.24)
19,20EpDPA	0.3 (0.4)	0.3 (0.3)	0.5 (0.4)	0.3 (1.0)	0.15 (0.11, 0.19)	0.06 (-0.03, 0.15)	0.09 (-0.01, 0.19)
<b>EPA and EPA derived metabolites</b>							
Total EPA	0.5 (0.2)	0.5 (0.2)	0.5 (0.2)	0.4 (0.2)	-0.03 (-0.05, -0.01)	-0.16 (-0.18, -0.15)	0.13 (0.11, 0.16)
Free EPA	0.1 (0.1)	0.1 (0.1)	0.1 (0.1)	0.1 (0.0)	0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.02)	0.03 (0.02, 0.04)
18-HEPE	2.5 (3.4)	2.4 (2.7)	0.9 (0.9)	0.7 (0.5)	-1.54 (-1.81, -1.28)	-1.77 (-1.97, -1.56)	0.22 (-0.11, 0.56)
<b>Omega-3<sup>†</sup></b>							
Omega-3 <sup>†</sup>	4.9 (0.8)	4.9 (1.0)	5.2 (1.2)	4.2 (0.8)	0.31 (0.20, 0.41)	-0.75 (-0.82, -0.67)	1.05 (0.92, 1.18)
Free omega-3 <sup>†</sup>	1.1 (0.6)	1.1 (0.5)	0.9 (0.5)	0.7 (0.3)	-0.18 (-0.24, -0.12)	-0.42 (-0.46, -0.38)	0.24 (0.17, 0.31)
<b>OMEGA-6 FATTY ACIDS</b>							
<b>AA and AA derived metabolites</b>							
Total AA	8.2 (1.2)	8.2 (1.2)	6.0 (1.0)	6.2 (1.1)	-2.24 (-2.33, -2.15)	-2.03 (-2.12, -1.94)	-0.20 (-0.33, -0.08)
Free AA	1.2 (0.7)	1.2 (0.6)	0.9 (0.4)	0.9 (0.4)	-0.34 (-0.40, -0.28)	-0.26 (-0.31, -0.21)	-0.08 (-0.16, 0.00)

<b>Fatty Acid or Oxylipin</b>	<b>Omega-3 Baseline Mean (SD)</b>	<b>Control Baseline Mean (SD)</b>	<b>Omega-3 34 weeks Mean (SD)</b>	<b>Control 34 weeks Mean (SD)</b>	<b>Omega-3 Group Effect*</b>	<b>Control Group Effect*</b>	<b>Difference**</b>
5-HETE	129.4 (121.7)	124.8 (81.2)	129.8 (78.4)	138.5 (71.4)	1.04 (-10.25, 12.34)	13.81 (5.32, 22.30)	-12.77 (-26.92, 1.38)
8-HETE	6.0 (5.5)	6.1 (3.9)	3.5 (2.2)	3.7 (1.8)	-2.40 (-2.85, -1.95)	-2.45 (-2.78, -2.13)	0.05 (-0.50, 0.61)
9-HETE	6.5 (5.4)	7.1 (6.1)	6.4 (4.7)	6.6 (4.3)	-0.09 (-0.65, 0.46)	-0.48 (-1.04, 0.08)	0.38 (-0.41, 1.18)
11-HETE	28.5 (28.0)	28.7 (19.2)	16.1 (10.7)	16.9 (9.4)	-12.26 (-14.53, -9.98)	-11.73 (-13.28, -10.17)	-0.53 (-3.30, 2.24)
12-HETE	133.0 (118.2)	142.9 (136.8)	76.4 (69.7)	77.8 (63.5)	-55.85 (-66.56, -45.15)	-64.92 (-76.04, -53.79)	9.06 (-6.42, 24.54)
15-HETE	8.6 (6.8)	8.7 (5.1)	4.5 (2.6)	4.8 (2.5)	-4.11 (-4.67, -3.56)	-3.88 (-4.30, -3.45)	-0.23 (-0.93, 0.47)
14,15-EET	2.1 (1.6)	2.1 (1.5)	1.2 (0.7)	1.4 (2.0)	-0.83 (-0.95, -0.70)	-0.70 (-0.90, -0.49)	-0.13 (-0.38, 0.12)
LTB4	3.2 (2.7)	3.1 (2.2)	1.8 (1.3)	1.9 (1.1)	-1.30 (-1.54, -1.07)	-1.19 (-1.38, -1.01)	-0.11 (-0.41, 0.19)
LXA4	0.3 (0.3)	0.3 (0.3)	0.6 (0.7)	0.6 (0.7)	0.29 (0.23, 0.35)	0.31 (0.24, 0.37)	-0.01 (-0.10, 0.07)
LXB4	3.8 (5.9)	3.6 (5.6)	15.5 (10.3)	15.0 (9.0)	11.76 (10.76, 12.77)	11.39 (10.52, 12.27)	0.37 (-0.96, 1.70)
Prostaglandin D2	10.6 (9.9)	9.7 (8.7)	2.8 (3.6)	2.5 (3.3)	-7.78 (-8.63, -6.94)	-7.26 (-7.99, -6.52)	-0.52 (-1.64, 0.60)
Thromboxane B2	7.7 (8.8)	8.0 (9.2)	1.6 (2.4)	1.7 (2.2)	-6.03 (-6.74, -5.33)	-6.27 (-6.98, -5.57)	0.24 (-0.76, 1.24)
<b>LA and LA derived metabolites</b>							
Total LA	19.4 (2.5)	19.3 (2.5)	19.5 (2.6)	19.0 (2.6)	0.06 (-0.15, 0.27)	-0.30 (-0.50, -0.09)	0.36 (0.06, 0.65)
Free LA	3.8 (2.5)	3.8 (2.1)	4.4 (2.4)	4.6 (2.4)	0.60 (0.34, 0.86)	0.82 (0.58, 1.07)	-0.22 (-0.58, 0.14)
9,10 EpHOME	6.7 (4.8)	6.8 (5.2)	2.1 (1.4)	2.3 (2.3)	-4.59 (-4.98, -4.21)	-4.53 (-4.96, -4.09)	-0.06 (-0.65, 0.52)
9-Oxooode	53.4 (44.3)	54.6 (36.6)	15.4 (9.4)	16.6 (10.6)	-37.94 (-41.43, -34.45)	-38.02 (-40.94, -35.11)	0.08 (-4.46, 4.63)
13-HODE	97.9 (81.5)	100.3 (71.3)	35.4 (19.6)	37.5 (23.7)	-62.45 (-68.94, -55.97)	-62.72 (-68.38, -57.05)	0.27 (-8.37, 8.90)
12,13DiHOME	1.2 (1.3)	1.1 (1.2)	0.6 (0.6)	0.7 (0.7)	-0.51 (-0.63, -0.39)	-0.47 (-0.57, -0.36)	-0.04 (-0.20, 0.11)

\* Values are estimated difference in the mean fatty acid or oxylipin concentrations (95% confidence interval) for 34 weeks' vs baseline adjusted for enrolment centre and recent omega-3 supplementation. Positive values indicate fatty acid or oxylipin concentrations are increasing over time. Negative values indicate fatty acid or oxylipin concentrations are decreasing over time.

\*\* Values are estimated difference in the mean change in fatty acid or oxylipin concentrations over time (95% confidence interval) for omega-3 vs control adjusted for enrolment centre and recent omega-3 supplementation.

†Omega-3 fatty acids, sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.

LA, linoleic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.



**Supplementary Table 4: Effect of high vs low baseline total omega-3 status (>4.9% vs ≤4.1%), treatment group and time on concentration of DHA & oxylipins and total omega-3.**

<b>Precursor Fatty Acid</b>	<b>Fatty Acid or Oxylipin</b>	<b>Omega-3 Group Effect*</b>	<b>Control Group Effect*</b>	<b>Difference**</b>
DHA	Total DHA	-0.35 (-0.59, -0.11)	-0.56 (-0.68, -0.45)	0.22 (-0.05, 0.48)
	Free DHA	0.14 (-0.00, 0.28)	-0.06 (-0.14, 0.02)	0.19 (0.03, 0.35)
	4-HDHA	7.55 (1.08, 14.02)	-1.12 (-4.12, 1.87)	8.68 (1.55, 15.80)
	7-HDHA	0.46 (0.23, 0.70)	0.08 (-0.07, 0.22)	0.39 (0.11, 0.67)
	14-HDHA	-0.71 (-3.17, 1.76)	-2.71 (-4.65, -0.76)	2.00 (-1.13, 5.13)
	19,20EpDPA	0.10 (0.01, 0.19)	0.11 (-0.09, 0.31)	-0.01 (-0.23, 0.21)
Omega-3 <sup>†</sup>	Omega-3 <sup>†</sup>	-0.77 (-1.08, -0.47)	-1.06 (-1.28, -0.85)	0.29 (-0.08, 0.66)
	Free Omega-3 <sup>†</sup>	0.19 (0.02, 0.36)	-0.06 (-0.15, 0.04)	0.24 (0.05, 0.44)


\* Values are estimated difference in the mean fatty acid or oxylipin concentrations (95% confidence interval) for 34 weeks' vs baseline between baseline total omega-3 status >4.9% and ≤4.1%, adjusted for enrolment centre and recent omega-3 supplementation.

\*\* Values are estimated difference in the mean change in fatty acid or oxylipin concentrations over time (95% confidence interval) for omega-3 vs control between baseline total omega-3 status >4.9% and ≤4.1%, adjusted for enrolment centre and recent omega-3 supplementation.


DHA, docosahexaenoic acid.

<sup>†</sup>Omega-3 fatty acids, sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.


**Supplementary Figure 1. Effect of baseline total omega-3 status, treatment group and time on concentration of free DHA.**




**Supplementary Figure 2. Effect of baseline total omega-3 status, treatment group and time on concentration of 4-HDHA.**



**Supplementary Figure 3. Effect of baseline total omega-3 status, treatment group and time on concentration of 7-HDHA.**



**Supplementary Figure 4. Effect of baseline total omega-3 status, treatment group and time on concentration of free total omega-3.**



Omega-3 = sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.